Indivior said the open-label, U.K. Phase I RB-EU-14-0001 trial in healthy volunteers showed that oral RBP-6300 did not achieve “the anticipated PK profile in humans to justify proceeding further with this technology.” Indivior plc (LSE:INDV),...

Reckitt Benckiser disclosed in its 2Q14 earnings that it plans to spin out Reckitt Benckiser Pharmaceuticals Inc. - its pharmaceutical business - with a separate listing on the London Stock Exchange over the next 12...

Reckitt Benckiser Group plc (LSE:RB) disclosed in its 2Q14 earnings that it plans to spin out Reckitt Benckiser Pharmaceuticals Inc. -- its pharmaceutical business -- with a separate listing on the London Stock Exchange over...